EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$9.10 USD
+0.22 (2.48%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $9.09 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for EYEPOINT PHARMACEUTICALS, INC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -70.80 | -102.25 | -58.42 | -45.39 | -56.79 |
Depreciation/Amortization & Depletion | -0.39 | 22.59 | 3.40 | 3.39 | 3.20 |
Net Change from Assets/Liabilities | 58.88 | -3.02 | -1.74 | 20.14 | -12.54 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 14.18 | 17.69 | 6.66 | 7.43 | 9.43 |
Net Cash From Operating Activities | 1.88 | -65.01 | -50.10 | -14.44 | -56.70 |
Property & Equipment | -3.48 | -2.15 | -0.16 | -0.36 | -0.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.17 | -15.12 | -32.97 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -3.32 | -17.27 | -33.12 | -0.36 | -0.21 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 229.55 | 0.40 | 217.20 | 50.21 | 23.04 |
Issuance (Repayment) of Debt | -40.51 | 2.10 | -0.15 | -11.80 | 30.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.97 | -3.19 | -0.15 | -0.92 | -19.18 |
Net Cash from Financing Activities | 187.07 | -0.69 | 216.90 | 37.49 | 33.86 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 185.63 | -82.96 | 133.68 | 22.70 | -23.05 |
Cash at Beginning of Period | 95.78 | 178.74 | 45.06 | 22.36 | 45.41 |
Cash at End of Period | 281.41 | 95.78 | 178.74 | 45.06 | 22.36 |
Diluted Net EPS | -1.82 | -2.74 | -2.03 | -3.54 | -5.40 |
Fiscal Year End for EYEPOINT PHARMACEUTICALS, INC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -60.11 | -29.28 | -70.80 | -56.70 | -44.08 |
Depreciation/Amortization & Depletion | -1.60 | -0.27 | -0.39 | 0.02 | -0.06 |
Net Change from Assets/Liabilities | -11.03 | -14.31 | 58.88 | 71.16 | 77.45 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.39 | 12.70 | 14.18 | 10.51 | 6.88 |
Net Cash From Operating Activities | -51.35 | -31.17 | 1.88 | 24.98 | 40.19 |
Property & Equipment | -2.09 | -1.19 | -3.48 | -2.60 | -0.88 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -137.50 | 22.00 | 0.17 | 46.43 | 46.43 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -139.59 | 20.81 | -3.32 | 43.83 | 45.55 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.19 | 4.56 | 229.55 | 11.03 | 0.25 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -40.51 | -40.51 | -40.51 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -4.74 | -4.45 | -1.97 | -1.93 | -1.52 |
Net Cash from Financing Activities | 0.44 | 0.12 | 187.07 | -31.42 | -41.78 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -190.49 | -10.25 | 185.63 | 37.40 | 43.96 |
Cash at Beginning of Period | 281.41 | 281.41 | 95.78 | 95.78 | 95.78 |
Cash at End of Period | 90.92 | 271.16 | 281.41 | 133.19 | 139.75 |
Diluted Net EPS | -0.58 | -0.55 | -0.32 | -0.33 | -0.61 |